Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine
about
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasisExperimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocolOver-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovaniLeishmanicidal activities of novel methylseleno-imidocarbamatesIncreased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stressNew trends in aminoglycosides use.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Antimalarial and antimicrobial activities of 8-Aminoquinoline-Uracils metal complexes.Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.Chemotherapy of leishmaniasis: present challenges.Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).Expression Analysis of Multiple Genes May Involve in Antimony Resistance among Leishmania major Clinical Isolates from Fars Province, Central Iran.Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Anti-leishmanial activity of heteroleptic organometallic Sb(v) compoundsComparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovaniVisceral Leishmaniasis - Current Treatments and Needs
P2860
Q28483875-4A030284-7C7C-4B54-B5E1-86D98842F81AQ28483977-42C15D30-C481-4653-8744-7DFCFC0B3A3BQ28547415-3EACEF44-EB3F-4FCF-9BFC-A5C2136B2A08Q30389497-F74AAE5B-8529-4534-B309-8E6486949F15Q33797614-1BE98CEC-D203-4F0A-847F-B8E60AEDD183Q33951177-C96F1E13-951A-4FE8-9461-4002828B9CD7Q34328882-D7B3B6DF-5CDA-4D22-B2F2-4CDC8EB0AFCCQ36806815-12FD22F4-0CEA-46D2-9D67-28305BC97258Q37712969-F1AF0813-CB4E-458D-81B5-9AA249131A2EQ39011875-5E9F8988-FFED-4FAD-81D1-A6AFC1952C6BQ39599468-56DBA2A5-F695-48B7-8EED-72B6C89B7DFAQ40368271-12C2864F-861C-4EEC-9053-23DEE32AEE4AQ42379574-3681831E-7102-4072-896F-0440C15B9F0AQ42548785-F54A05B0-9546-4533-852B-C7C5B858502AQ47548487-865518D4-0BFB-4FA4-A760-BFE417927188Q57240632-78A55FA5-F15A-45A5-A6E9-E943331B1063Q59003551-7C5DCA31-3275-440B-9D0F-78CE7418513EQ59003562-11922998-30DD-451B-BF0B-E42F13FAE7CC
P2860
Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@ast
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@en
type
label
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@ast
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@en
prefLabel
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@ast
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@en
P2093
P2860
P356
P1476
Antimony-resistant clinical is ...... to paromomycin and sitamaquine
@en
P2093
Arpita Kulshrestha
Dhiraj Kumar
Narender Singh Negi
P2860
P304
P356
10.1128/AAC.00812-10
P407
P577
2011-04-04T00:00:00Z